Guizhou Bailing Group Pharmaceutical Co., Ltd. (002424.SZ)

Guizhou Bailing Group Pharmaceutical Co., Ltd. (002424.SZ) — VMCI valuation read

Composite valuation read on 002424.SZ: VMCI 38/100 against a Healthcare sector median of 50. The 13-point below-median print is the headline number for Guizhou Bailing Group Pharmaceutical Co., Ltd., and at the mid-cap tier it reflects how the five pillars combine into a single decision-grade score.

Trailing 30-day insider activity for 002424.SZ: nothing material on SEC EDGAR. With the Form 4 channel quiet, the price-vs-DCF gap and the trailing margin trend carry more weight in the active read.

**Investor frame.** Value, quality, risk in three lines on 002424.SZ: 002424.SZ trades at 23.0x earnings, 28% above the Healthcare median of 18.0x; ROIC of 17.0% sits 7.0pp above the Healthcare median (10.0%); net debt to EBITDA of 2.3x is the rate-sensitivity line to watch. EV/EBITDA at 14.0x versus 12.0x for Healthcare closes the value frame.

002424.SZ rose 3.6% over the trailing 7 days, with a -15.6% read on a 30-day basis.